COMP <GO>
RMD vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
ResMed Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RMD 8
— UNH 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: RMD
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
balance-sheet
12.49
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
balance-sheet
3.12
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RMD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RMD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.40% | 88.57% | -29.17 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.90% | 11.47% | +11.43 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.9x | 16.4x | +3.45 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 4.67% | 6.48% | -1.81 | UNH | /fcf-yield <GO> |
| Operating Margin | 32.70% | 4.82% | +27.88 | RMD | /operating-margins <GO> |
| Net Profit Margin | 27.20% | 3.14% | +24.06 | RMD | /net-margins <GO> |
| Revenue Growth (YoY) | 9.80% | 6.46% | +3.34 | RMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.87% | 2.28% | -1.41 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.49 | 3.12 | +9.37 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | RMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.74% | -0.04 | RMD | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 56.0 | -14.29 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 0.33 | +0.60 | RMD | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.6x | 17.1x | +6.51 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.56B | $364.66B | -$329.10B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RMD REV | UNH REV | RMD GROSS % | UNH GROSS % | RMD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.15B | $447.57B | 59.4% | 88.7% | $1.66B | $16.07B |
| FY 2024 | $4.69B | $400.28B | 56.7% | 88.3% | $1.30B | $20.70B |
| FY 2023 | $4.22B | $371.62B | 44.0% | 89.6% | $503.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RMD // BETA 0.93
UNH // BETA 0.33